MenoGeniX is a clinical-stage biotech company dedicated to women’s health focused on developing a novel potential treatment for women suffering from hot flashes and related vasomotor symptoms of menopause.
Located in Aurora, Colorado and adjacent to the University of Colorado Anschutz Medical Campus, MenoGeniX began operations in 2012 and filed a series of U.S. and international patent applications. Patents have been issued in the U.S., Australia, Canada, China, Europe, Israel and Japan.
MenoGeniX completed a Phase I clinical trial to investigate the safety and effectiveness of MNGX-100 for treating hot flashes in women with naturally occurring and surgically induced menopause. The trial produced positive results, informing the design for a larger Phase Ib/IIa trial that is being funded by a grant from the National Institutes of Health (NIH).